Commercial Impact of the Loss of Exclusivity of an Orphan Drug and Generic Strategies in France

CHALLENGE

A top 10 pharmaceutical company engaged a boutique consulting firm to evaluate the commercial impact of the loss of exclusivity for an orphan drug and explore generic strategies in France. The aim was to provide an in-depth analysis of how the expiry of exclusivity affects market dynamics and the strategies employed by generic companies.

BTHT APPROACH

Following a detailed briefing with the consulting firm and a clear understanding of the project's scope, the BTHT team identified and reached out to former General Managers and CEOs of generic drug companies. These experts were selected for their extensive experience and insights into the commercial and strategic aspects of the generics market. The BTHT team organized and facilitated a series of expert calls, ensuring that each conversation was both comprehensive and free from technical disruptions.

OUTCOME

The BTHT team successfully facilitated insightful discussions with seasoned former General Managers and CEOs of generic companies. These expert calls provided the client with a deep understanding of the commercial repercussions of an orphan drug’s loss of exclusivity, including market shifts, competitive strategies, and impact on pricing and access. The high-quality insights gathered were crucial for the consulting firm to deliver a thorough and actionable assessment, supporting the pharmaceutical company in navigating the complexities of the generics market in France.